| __timestamp | Pharming Group N.V. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 4042025 | 5078000000 |
| Thursday, January 1, 2015 | 5279557 | 4717000000 |
| Friday, January 1, 2016 | 8073913 | 5096000000 |
| Sunday, January 1, 2017 | 44864073 | 4986000000 |
| Monday, January 1, 2018 | 53488904 | 4214000000 |
| Tuesday, January 1, 2019 | 65896361 | 3806000000 |
| Wednesday, January 1, 2020 | 69968267 | 3671000000 |
| Friday, January 1, 2021 | 92047281 | 3528000000 |
| Saturday, January 1, 2022 | 131819000 | 3445000000 |
| Sunday, January 1, 2023 | 87501000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Igniting the spark of knowledge
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This analysis compares the SG&A expenses of Teva Pharmaceutical Industries Limited and Pharming Group N.V. from 2014 to 2023.
Teva, a global leader, consistently reported higher SG&A expenses, peaking in 2016 with nearly 5.1 billion USD. However, a downward trend is evident, with a 32% reduction by 2023. This reflects Teva's strategic cost-cutting measures amidst industry challenges.
Conversely, Pharming Group N.V., a smaller player, saw a dramatic increase in SG&A expenses, rising over 2,000% from 2014 to 2022. This surge aligns with Pharming's expansion efforts and increased market presence.
Understanding these trends offers insights into each company's strategic priorities and market positioning, highlighting the dynamic nature of the pharmaceutical industry.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Pharming Group N.V.
Comparing SG&A Expenses: Novartis AG vs Pharming Group N.V. Trends and Insights
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Bio-Techne Corporation
Teva Pharmaceutical Industries Limited vs Viking Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Mesoblast Limited
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Teva Pharmaceutical Industries Limited vs Celldex Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Pharming Group N.V.
Comparing SG&A Expenses: Pharming Group N.V. vs Catalyst Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Pharming Group N.V. vs BioCryst Pharmaceuticals, Inc.